Sean M. Healey & AMG Center for ALS Announces First participant Dosed in Regimen G of the HEALEY ALS Platform Trial Evaluating DNL343 by Denali Therapeutics
DNL343 is a novel investigational ALS therapy that targets eIF2B, a central regulator of the integrated stress response (ISR).